COVID-19

The FDA also expanded the pediatric emergency use authorization for remdesivir to include the treatment of non-hospitalized pediatric patients at high risk of disease progression.

This recent research also found that those who received the Moderna vaccine were less likely to be hospitalized compared to recipients of the Pfizer-BioNTech vaccine.

Stanford Medicine investigators were able to estimate who is most likely to land in the hospital.

Results of an analysis show that 3 doses of either Oxford/AstraZeneca COVID-19 or Pfizer BioNTech COVID-19 neutralizes the variant.

Further, the Index is based on proprietary data from PCR testing services administered by Walgreens.

Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discussed what the impact of the pandemic has been on the advancement of data interoperability in health care.

A sizable number of clinical trial participants say they had at least 1 AE, with fatigue and headaches the most common.

The analysis describes cost-effective options for individuals without symptoms and recommends isolation strategies to help policymakers safeguard against resurgences.

Patients can sometimes develop Guillain-Barre syndrome after having a recent respiratory illness or digestive tract infection and, in rare cases, after receiving certain vaccines.

The Biden administration announced that it would make 400 million nonsurgical N95 masks for US citizens available free of charge at community health centers and retail pharmacies across the United States.

Results from multiple studies show that the effectiveness of nirmatrelvir, the active main protease inhibitor of Paxlovid is maintained.

Study results show that unvaccinated pregnant women with the disease are more likely to experience poor childbirth outcomes, even if they did not have severe respiratory problems.

Ending the COVID-19 pandemic requires an understanding of how to manage the inflammatory dysfunction that the virus causes.

Study results show health plans paid most of the drug costs, despite the lack of effect seen on COVID-19.

The World Health Organization issues a strong recommendation for baricitinib and a conditional one for sotrovimab.

Monoclonal antibodies and emerging agents may avert severe illness, especially for high-risk individuals.

A new analysis suggests that boosters can provide ongoing prevention of death and hospitalization.

Most pharmacists see a transition from transactional care to more direct patient care responsibilities.

For the acceptance of a combination COVID-19 flu vaccine, the team asked participants whether they would be willing to take a combination COVID-19-flu vaccine as a single-shot every year.

Based on the results, the investigators found that a cloth face covering reduced emissions in all directions to about 2 feet compared to the 4 feet of emissions produced when coughing or speaking with no mask on.

Responses elicited by the pneumococcal vaccine for all 20 serotypes were similar whether administered with the COVID-19 vaccine or with placebo.

Well-designed incentives and education can help address COVID-19 vaccine hesitancy and bolster vaccination rates.

Earlier analyses also demonstrated the same potential of BBV152 against SARS-CoV-2 alpha, beta, delta, zeta, and kappa.

These individuals also receive immunosuppressive drugs that often impair the immune responses to the vaccinations, study results show.

Ensovibep has met the primary endpoint of viral load reduction over 8 days in a phase 2 study, the companies said.

Study strongly supports the CDC’s guidance that booster shots are appropriate for anyone ages 16 and older, and that mRNA vaccines are preferred.

A single shot protects for up to 6 months against breakthrough infections, hospitalizations, and intensive care unit admissions, Johnson & Johnson says.

Out of the 3959 who were a part of the study, 2403 of the individuals were vaccinated and 1556 were unvaccinated.

The recommendations include full immunization, including third doses and/or any approved boosters.

Results of a separate analysis demonstrate that Johnson & Johnson’s booster generated a 41-fold increase in neutralizing antibodies and a 5-fold increase in T-cells against omicron.